SPARCL1 and breast cancer: The correlation between SPARCL1 levels and the clinical characteristics of patients with BC was further analyzed and showed that the lower SPARCL1 expression was significantly related to age, tumor-node-metastasis (TNM) stage, estrogen receptor (ER) status, progesterone receptor (PR) status, histological type, molecular type, and living status, whereas no significant difference in node stage and Her-2 status was observed (Table 3).